NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $559 | -14.5% | 522,327 | +106.8% | 0.00% | 0.0% |
| Q2 2023 | $654 | -51.3% | 252,600 | -23.3% | 0.00% | -50.0% |
| Q1 2023 | $1,344 | -22.0% | 329,500 | -4.1% | 0.00% | 0.0% |
| Q4 2022 | $1,724 | -100.0% | 343,500 | +25.3% | 0.00% | -60.0% |
| Q3 2022 | $3,587,000 | -17.3% | 274,200 | -19.0% | 0.01% | 0.0% |
| Q2 2022 | $4,338,000 | +82.7% | 338,368 | +117.3% | 0.01% | +66.7% |
| Q1 2022 | $2,374,000 | +79.4% | 155,700 | +108.4% | 0.00% | +50.0% |
| Q4 2021 | $1,323,000 | +372.5% | 74,700 | +461.7% | 0.00% | – |
| Q3 2021 | $280,000 | -78.6% | 13,300 | -83.8% | 0.00% | -100.0% |
| Q3 2020 | $1,308,000 | -60.8% | 82,200 | -51.4% | 0.00% | -66.7% |
| Q2 2020 | $3,336,000 | +81.5% | 169,000 | +13.3% | 0.00% | +50.0% |
| Q1 2020 | $1,838,000 | – | 149,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |